Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine, an ABCG2 inhibitor and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine and an ABCG2 inhibitor.
Type:
Application
Filed:
February 7, 2019
Publication date:
January 9, 2020
Applicant:
Glialogix, Inc.
Inventors:
Thaddeus Cromwell Reeder, Mark W. Moore, David K. Lyon, Casey K. Jager, Doug Lorenz, Corey Bloom, Kimberley Shepard
Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
Type:
Grant
Filed:
April 17, 2018
Date of Patent:
September 3, 2019
Assignee:
Glialogix, Inc.
Inventors:
Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
Type:
Application
Filed:
April 17, 2018
Publication date:
January 17, 2019
Applicant:
Glialogix, Inc.
Inventors:
Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
Type:
Grant
Filed:
November 30, 2016
Date of Patent:
May 29, 2018
Assignee:
GLIALOGIX, INC.
Inventors:
Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
Type:
Grant
Filed:
November 30, 2016
Date of Patent:
May 22, 2018
Assignee:
GLIALOGIX, INC.
Inventors:
Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine, an ABCG2 inhibitor and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine and an ABCG2 inhibitor.
Type:
Application
Filed:
October 20, 2017
Publication date:
April 26, 2018
Applicant:
Glialogix, Inc.
Inventors:
Thaddeus Cromwell Reeder, Mark W. Moore, David K. Lyon, Casey K. Jager, Doug Lorenz, Corey Bloom, Kimberly Shepard
Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
Type:
Grant
Filed:
February 10, 2017
Date of Patent:
March 20, 2018
Assignee:
GLIALOGIX, INC.
Inventors:
Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
Type:
Grant
Filed:
January 31, 2014
Date of Patent:
March 21, 2017
Assignee:
GLIALOGIX, INC.
Inventors:
Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
Type:
Application
Filed:
January 31, 2014
Publication date:
August 7, 2014
Applicant:
Glialogix, Inc.
Inventors:
Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon